Niagen Bioscience, Inc. Cash Flow Conversion Efficiency
Niagen Bioscience, Inc. cash flow conversion efficiency. Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has a cash flow conversion efficiency ratio of 0.034x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.77 Million) by net assets ($82.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Niagen Bioscience, Inc. (2007–2025)
Cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2025. This chart illustrates how Niagen Bioscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Niagen Bioscience, Inc. stock price for real-time trading data and today's change.
Niagen Bioscience, Inc. Cash Flow Conversion Ratio Explained
Niagen Bioscience, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Niagen Bioscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niagen Bioscience, Inc. ranked by their cash flow conversion efficiency. Also see NAGE stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Provident Agro Tbk
JK:PALM
|
0.279x |
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
0.040x |
|
Eureka Group Holdings Ltd
AU:EGH
|
0.029x |
|
SOL-GEL TECHN. IS-10
F:4SG
|
N/A |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
0.034x |
|
Lotus Technology Inc.
NASDAQ:LOT
|
0.639x |
|
Korea Asset In Trust Co Ltd
KO:123890
|
0.070x |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
0.063x |
Annual Cash Flow Conversion Efficiency for Niagen Bioscience, Inc. (2007–2025)
The table below shows the annual cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2025. Review cash generation quality of Niagen Bioscience, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $76.53 Million | $13.44 Million | 0.176x | -33.17% |
| 2024-12-31 | $46.09 Million | $12.11 Million | 0.263x | +5.04% |
| 2023-12-31 | $28.46 Million | $7.12 Million | 0.250x | +147.50% |
| 2022-12-31 | $28.67 Million | $-15.10 Million | -0.527x | +30.86% |
| 2021-12-31 | $31.73 Million | $-24.16 Million | -0.762x | -18.00% |
| 2020-12-31 | $16.42 Million | $-10.60 Million | -0.645x | +35.44% |
| 2019-12-31 | $20.45 Million | $-20.44 Million | -1.000x | -29.95% |
| 2018-12-31 | $27.18 Million | $-20.91 Million | -0.769x | -322.42% |
| 2017-12-31 | $53.83 Million | $-9.80 Million | -0.182x | +38.14% |
| 2016-12-31 | $9.97 Million | $-2.94 Million | -0.294x | +26.44% |
| 2015-12-31 | $5.27 Million | $-2.11 Million | -0.400x | +37.98% |
| 2014-12-31 | $4.00 Million | $-2.58 Million | -0.645x | +6.39% |
| 2013-12-31 | $5.67 Million | $-3.91 Million | -0.689x | +72.79% |
| 2012-12-31 | $3.99 Million | $-10.12 Million | -2.534x | -58.35% |
| 2011-12-31 | $2.56 Million | $-4.10 Million | -1.600x | -196.80% |
| 2010-12-31 | $4.94 Million | $-2.66 Million | -0.539x | -42.56% |
| 2009-12-31 | $1.05 Million | $-396.17K | -0.378x | +65.57% |
| 2008-12-31 | $1.75 Million | $-1.92 Million | -1.098x | +99.49% |
| 2007-12-31 | $180.00 | $-38.48K | -213.794x | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulat… Read more